Carlo Pozzilli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5439692/publications.pdf

Version: 2024-02-01

322 papers	18,320 citations	10956 71 h-index	18606 119 g-index
326 all docs	326 docs citations	326 times ranked	13623 citing authors

#	Article	IF	Citations
1	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
2	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Medicine, 2000, 6, 1176-1182.	15.2	506
3	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	2.8	370
4	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex^{Â®}), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 2011, 18, 1122-1131.	1.7	364
5	Diffusion-Weighted Imaging Tractography-Based Parcellation of the Human Lateral Premotor Cortex Identifies Dorsal and Ventral Subregions with Anatomical and Functional Specializations. Journal of Neuroscience, 2007, 27, 10259-10269.	1.7	303
6	fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. NeuroImage, 2004, 21, 858-867.	2.1	285
7	Multiple sclerosis in childhood: clinical features of 149 cases. Multiple Sclerosis Journal, 1997, 3, 43-46.	1.4	275
8	Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology, 1997, 244, 153-159.	1.8	257
9	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	4.9	247
10	Progressing Neurological Deficit Secondary to Acute Ischemic Stroke. Archives of Neurology, 1995, 52, 670.	4.9	245
11	Assessing walking disability in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 914-924.	1.4	236
12	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.5	227
13	Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. European Journal of Neurology, 2005, 12, 817-827.	1.7	226
14	Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet, The, 2004, 364, 1149-1156.	6.3	181
15	Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain, 2002, 125, 1607-1615.	3.7	171
16	A mechanism-based classification of pain in multiple sclerosis. Journal of Neurology, 2013, 260, 351-367.	1.8	157
17	Home-Based Balance Training Using the Wii Balance Board. Neurorehabilitation and Neural Repair, 2013, 27, 516-525.	1.4	151
18	Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences, 2004, 218, 103-108.	0.3	146

#	Article	IF	Citations
19	Structural and functional bases for individual differences in motor learning. Human Brain Mapping, 2011, 32, 494-508.	1.9	136
20	Prospective study of multiple sclerosis with early onset. Multiple Sclerosis Journal, 2002, 8, 115-118.	1.4	134
21	Realâ€life impact of early interferonÎ² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	2.8	132
22	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. JAMA Neurology, 2021, 78, 558.	4.5	132
23	Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1198-1208.	0.9	130
24	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 82, 41-48.	1.5	128
25	Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study. NeuroImage, 1996, 4, 87-96.	2.1	127
26	â€˜Gender gapâ€™ in multiple sclerosis: magnetic resonance imaging evidence. European Journal of Neurology, 2003, 10, 95-97.	1.7	126
27	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	1.4	126
28	The Diagnostic Accuracy of Static Posturography in Predicting Accidental Falls in People With Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2013, 27, 45-52.	1.4	123
29	Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke.. Stroke, 1990, 21, 895-900.	1.0	122
30	Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. Journal of the Neurological Sciences, 2004, 222, 99-104.	0.3	122
31	Oneâ€year MRI scan predicts clinical response to interferon beta in multiple sclerosis. European Journal of Neurology, 2009, 16, 1202-1209.	1.7	122
32	Imaging of leukocytic infiltration in human cerebral infarcts.. Stroke, 1985, 16, 251-255.	1.0	120
33	Multiple Sclerosis: Altered Thalamic Resting-State Functional Connectivity and Its Effect on Cognitive Function. Radiology, 2014, 271, 814-821.	3.6	116
34	Predictors of longâ€“term clinical response to interferon beta therapy in relapsing multiple sclerosis. Journal of Neurology, 2006, 253, 287-293.	1.8	113
35	Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 783-791.	1.4	113
36	Factors Affecting Course and Survival in Alzheimer's Disease. Archives of Neurology, 1994, 51, 1213.	4.9	112

#	Article	IF	Citations
37	Effect of corpus callosum damage on ipsilateral motor activation in patients with multiple sclerosis: A functional and anatomical study. Human Brain Mapping, 2007, 28, 636-644.	1.9	112
38	Brain atrophy in relapsing-remitting multiple sclerosis: relationship with â€˜black holesâ€™, disease duration and clinical disability. Journal of the Neurological Sciences, 2000, 174, 85-91.	0.3	110
39	Contribution of Corticospinal Tract Damage to Cortical Motor Reorganization after a Single Clinical Attack of Multiple Sclerosis. NeuroImage, 2002, 17, 1837-1843.	2.1	107
40	CMRO₂ and CBF by the Oxygen-15 Inhalation Technique. European Neurology, 1981, 20, 285-290.	0.6	104
41	Fatigue and magnetic resonance imaging activity in multiple sclerosis. Journal of Neurology, 1999, 246, 454-458.	1.8	104
42	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.5	102
43	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424.	1.4	99
44	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
45	Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clinical Rehabilitation, 2007, 21, 331-337.	1.0	96
46	Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients. PLoS ONE, 2013, 8, e63250.	1.1	92
47	Spontaneous Middle Cerebral Artery Reperfusion in Ischemic Stroke. Stroke, 1995, 26, 430-433.	1.0	90
48	Multiple Sclerosis: Changes in Microarchitecture of White Matter Tracts after Training with a Video Game Balance Board. Radiology, 2014, 273, 529-538.	3.6	88
49	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.5	88
50	A longitudinal fMRI study on motor activity in patients with multiple sclerosis. Brain, 2005, 128, 2146-2153.	3.7	87
51	Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis. Clinical Neuropharmacology, 2009, 32, 41-47.	0.2	87
52	Anterior Corpus Callosum Atrophy and Verbal Fluency in Multiple Sclerosis. Cortex, 1991, 27, 441-445.	1.1	86
53	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86
54	T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain, 2001, 124, 1396-1402.	3.7	85

#	Article	IF	Citations
55	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 64-71.	1.4	85
56	Monthly corticosteroids decrease neutralizing antibodies to IFNÎ²1b: a randomized trial in multiple sclerosis. Journal of Neurology, 2002, 249, 50-56.	1.8	83
57	Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Review of Neurotherapeutics, 2013, 13, 49-54.	1.4	83
58	A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magnetic Resonance Imaging, 2002, 20, 383-388.	1.0	82
59	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	0.8	82
60	A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology, 2016, 86, 2094-2099.	1.5	79
61	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Multiple Sclerosis Journal, 2005, 11, 441-446.	1.4	78
62	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	0.8	78
63	The relationship between infratentorial lesions, balance deficit and accidental falls in multiple sclerosis. Journal of the Neurological Sciences, 2011, 304, 55-60.	0.3	77
64	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	1.4	77
65	Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacological Research, 2013, 67, 1-9.	3.1	77
66	Involvement of the limbic system in multiple sclerosis patients with depressive disorders. Biological Psychiatry, 1996, 39, 970-975.	0.7	76
67	Multiple Sclerosis: White and Gray Matter Damage Associated with Balance Deficit Detected at Static Posturography. Radiology, 2013, 268, 181-189.	3.6	76
68	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	3.7	76
69	Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. European Journal of Immunology, 1993, 23, 1232-1239.	1.6	74
70	The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2007, 192, 174-183.	1.1	74
71	Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Voxelwise Regional Investigation of White and Gray Matter. Radiology, 2010, 254, 227-234.	3.6	74
72	Gray- and White-Matter Changes 1 Year after First Clinical Episode of Multiple Sclerosis: MR Imaging. Radiology, 2010, 257, 448-454.	3.6	74

#	Article	IF	Citations
73	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.5	74
74	Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurologica Scandinavica, 2002, 106, 109-112.	1.0	73
75	Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurology, 2015, 15, 174.	0.8	72
76	Peripheral white blood cell count in cerebral ischemic infarction. Acta Neurologica Scandinavica, 1985, 71, 396-400.	1.0	71
77	Simplified, Noninvasive PET Measurement of Blood-Brain Barrier Permeability. Journal of Computer Assisted Tomography, 1987, 11, 390-397.	0.5	70
78	Preservation of motor skill learning in patients with multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 103-115.	1.4	69
79	Advances in spinal cord imaging in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984059.	1.5	69
80	The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurology, 2004, 251, 432-439.	1.8	68
81	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	0.9	68
82	Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-Î²1a. Journal of Interferon and Cytokine Research, 1998, 18, 345-350.	0.5	67
83	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	0.9	66
84	A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. European Journal of Neurology, 2002, 9, 645-655.	1.7	65
85	Oral contraceptives combined with interferon Î² in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e120.	3.1	64
86	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	4.9	64
87	Intracortical excitability in patients with relapsingâ€“remitting and secondary progressive multiple sclerosis. Journal of Neurology, 2009, 256, 933-938.	1.8	63
88	T-lymphocyte reactivity to the recombinant mycobacterial 65- and 70-kDa heat shock proteins in multiple sclerosis. Journal of Autoimmunity, 1992, 5, 691-702.	3.0	61
89	Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. Journal of the Neurological Sciences, 1999, 168, 131-136.	0.3	61
90	Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. Journal of the Neurological Sciences, 2003, 215, 3-8.	0.3	61

#	Article	IF	Citations
91	Relating Brain Damage to Brain Plasticity in Patients With Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2012, 26, 581-593.	1.4	61
92	Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 491-499.	1.4	60
93	A Low-Cost Cognitive Rehabilitation With a Commercial Video Game Improves Sustained Attention and Executive Functions in Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 453-461.	1.4	60
94	Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology, 1999, 6, 455-459.	1.7	59
95	The effect of Bacille Calmette-GuÃ©rin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. Journal of Neurology, 2003, 250, 247-248.	1.8	59
96	Natalizumab treatment in pediatric multiple sclerosis: A case report. European Journal of Paediatric Neurology, 2009, 13, 67-71.	0.7	59
97	Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis â€" Results of the BetaPlus observational cohort study. Journal of the Neurological Sciences, 2011, 307, 120-126.	0.3	59
98	The immune response to Mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. Journal of Neuroimmunology, 1996, 65, 143-153.	1.1	58
99	Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 302-306.	1.4	58
100	Measurement of CBF and CMRO2 using the continuous inhalation of C15O2 and 15O2. Journal of the Neurological Sciences, 1981, 50, 381-389.	0.3	57
101	Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132.	0.9	57
102	Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. Journal of Neurochemistry, 2004, 88, 1179-1185.	2.1	56
103	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal, 2013, 19, 1106-1112.	1.4	56
104	Remote Effects of Subcortical Cerebrovascular Lesions: A SPECT Cerebral Perfusion Study. Journal of Cerebral Blood Flow and Metabolism, 1988, 8, 560-567.	2.4	55
105	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	2.8	55
106	Brain reorganization during attention and memory tasks in multiple sclerosis: Insights from functional MRI studies. Journal of the Neurological Sciences, 2006, 245, 93-98.	0.3	54
107	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	3.7	53
108	Relationship between emotional distress in caregivers and health status in persons with multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 442-446.	1.4	52

#	Article	IF	Citations
109	Sex hormones, brain damage and clinical course of Multiple Sclerosis. Journal of the Neurological Sciences, 2009, 286, 35-39.	0.3	52
110	A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year. Canadian Journal of Neurological Sciences, 1994, 21, 266-270.	0.3	50
111	Patterns of Cognitive Impairment in Secondary Progressive Stable Phase of Multiple Sclerosis: Correlations with MRI Findings. European Neurology, 2001, 45, 11-18.	0.6	50
112	Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis Journal, 2007, 13, 1086-1094.	1.4	50
113	Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. Acta Neurologica Scandinavica, 1992, 86, 354-358.	1.0	49
114	MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Multiple Sclerosis Journal, 2002, 8, 119-123.	1.4	49
115	Alexithymia in multiple sclerosis: relationship with fatigue and depression. Acta Neurologica Scandinavica, 2008, 118, 18-23.	1.0	48
116	Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program. Radiology, 2016, 280, 202-211.	3.6	48
117	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	1.5	48
118	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Multiple Sclerosis Journal, 2005, 11, 433-440.	1.4	47
119	Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. Journal of the Neurological Sciences, 2012, 323, 104-112.	0.3	47
120	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	0.8	47
121	Psychostimulant drugs increase glucose utilization in the shell of the rat nucleus accumbens. NeuroReport, 1994, 5, 2561-2564.	0.6	46
122	Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. Journal of Neurology, 1995, 242, 143-146.	1.8	46
123	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	0.9	46
124	Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 566-576.	1.4	45
125	Cannabinoidâ€induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. European Journal of Pain, 2009, 13, 472-477.	1.4	44
126	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44

#	Article	IF	Citations
127	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naÃ¯ve patients with multiple sclerosis. Journal of Neurology, 2017, 264, 284-294.	1.8	44
128	Corticosteroids treatment. Journal of the Neurological Sciences, 2004, 223, 47-51.	0.3	43
129	Primary headache and multiple sclerosis: preliminary results of a prospective study. Neurological Sciences, 2008, 29, 146-148.	0.9	43
130	Pulse monthly steroids during an elective interruption of natalizumab: a postâ€marketing study. European Journal of Neurology, 2012, 19, 783-787.	1.7	43
131	Functional connectivity changes and their relationship with clinical disability and white matter integrity in patients with relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1681-1692.	1.4	43
132	Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurologica Scandinavica, 2015, 131, 336-340.	1.0	43
133	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	0.9	42
134	Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases. Frontiers in Neurology, 2021, 12, 765954.	1.1	42
135	Mesial temporal cortex hypoperfusion is associated with depression in subcortical stroke.. Stroke, 1994, 25, 980-985.	1.0	41
136	Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1291-1297.	1.4	41
137	Remote Effects of Caudate Hemorrhage: A Clinical and Functional Study. Cortex, 1987, 23, 341-349.	1.1	40
138	Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Multiple Sclerosis Journal, 2003, 9, 342-348.	1.4	39
139	Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2016, 364, 145-147.	0.3	39
140	The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review. Multiple Sclerosis International, 2013, 2013, 1-9.	0.4	38
141	Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial. Clinical Rehabilitation, 2013, 27, 803-812.	1.0	38
142	Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 81-90.	1.4	38
143	Investigating the phenomenon of â€œcognitive-motor interferenceâ€• in multiple sclerosis by means of dual-task posturography. Gait and Posture, 2015, 41, 780-785.	0.6	38
144	Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. Journal of the Neurological Sciences, 1992, 112, 51-57.	0.3	37

#	Article	IF	Citations
145	Power spectrum analysis contribution to the detection of cardiovascular dysautonomia in multiple sclerosis. Acta Neurologica Scandinavica, 2009, 93, 241-245.	1.0	37
146	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs, 2020, 34, 973-988.	2.7	37
147	No increase of serum autoantibodies during therapy with recombinant human interferon-Î²1a in relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica, 1997, 96, 372-374.	1.0	36
148	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. Journal of Neurology, 2016, 263, 751-759.	1.8	35
149	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	1.8	35
150	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. CNS Drugs, 2018, 32, 963-970.	2.7	35
151	Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology, 2018, 91, e153-e161.	1.5	35
152	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. European Journal of Neurology, 2017, 24, 516-522.	1.7	34
153	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
154	Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features. Multiple Sclerosis Journal, 2017, 23, 546-555.	1.4	34
155	Influence of nimodipine on cerebral blood flow in human cerebral ischaemia. Journal of Neurology, 1989, 236, 199-202.	1.8	33
156	Observations during an elective interruption of natalizumab treatment: a post-marketing study. Multiple Sclerosis Journal, 2011, 17, 372-375.	1.4	33
157	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	1.4	32
158	Early use of high-efficacy diseaseâ€'modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	1.8	32
159	MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 221-225.	1.4	31
160	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	0.9	30
161	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	0.9	30
162	The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Human Brain Mapping, 2016, 37, 2431-2445.	1.9	29

#	Article	IF	Citations
163	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 271-277.	0.9	29
164	TRACKING OF INDIUM-111-OXINE LABELLED LYMPHOCYTES IN AUTOIMMUNE THYROID DISEASE. Clinical Endocrinology, 1983, 19, 111-116.	1.2	28
165	Serum amyloid A protein is elevated in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 1998, 88, 9-12.	1.1	28
166	Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. Journal of Neurology, 2012, 259, 2319-2328.	1.8	28
167	The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis. Headache, 2012, 52, 1130-1135.	1.8	28
168	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	0.8	27
169	Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	27
170	Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon Î² 1a. Journal of Neurology, 1999, 246, 443-448.	1.8	26
171	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	1.5	26
172	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	4.5	26
173	Structural Brain Correlates of Neurourologic Abnormalities in Multiple Sclerosis. European Neurology, 1992, 32, 228-230.	0.6	25
174	Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period. Clinical Neuropharmacology, 2008, 31, 167-172.	0.2	25
175	Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study. BMC Neurology, 2009, 9, 54.	0.8	25
176	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurological Sciences, 2017, 38, 53-59.	0.9	25
177	Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis. Radiology, 2018, 287, 267-275.	3.6	25
178	Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2004, 224, 23-27.	0.3	24
179	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon Î²1b therapy in relapsingâ€“remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	1.4	24
180	Predicting the profile of increasing disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1306-1315.	1.4	24

#	Article	IF	Citations
181	The distribution of magnetic resonance imaging response to interferonÎ²â€“1b in multiple sclerosis. Journal of Neurology, 2005, 252, 1455-1458.	1.8	23
182	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.3	23
183	Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurological Sciences, 2011, 31, 303-307.	0.9	23
184	Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Multiple Sclerosis Journal, 2013, 19, 411-417.	1.4	23
185	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Multiple Sclerosis Journal, 2015, 21, 1713-1722.	1.4	23
186	Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial. CNS Drugs, 2017, 31, 161-168.	2.7	23
187	Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Multiple Sclerosis Journal, 2005, 11, 390-394.	1.4	22
188	Sex hormones: a role in the control of multiple sclerosis?. Expert Opinion on Pharmacotherapy, 2006, 7, 857-868.	0.9	22
189	Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1432-1440.	1.4	22
190	Mood and coping in clinically isolated syndrome and multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 374-381.	1.0	22
191	The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurologica Scandinavica, 1997, 95, 201-207.	1.0	21
192	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Multiple Sclerosis Journal, 2016, 22, 944-954.	1.4	21
193	Relation between functional connectivity and disability in multiple sclerosis: a non-linear model. Journal of Neurology, 2018, 265, 2881-2892.	1.8	21
194	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology, 2019, 93, e733-e746.	1.5	21
195	Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. European Journal of Neurology, 2007, 14, 1281-1287.	1.7	20
196	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	1.8	20
197	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	1.7	20
198	Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?. BMC Neurology, 2011, 11, 26.	0.8	19

#	Article	IF	Citations
199	Structural Brain MR Imaging Changes Associated with Obsessive-Compulsive Disorder in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2013, 34, 305-309.	1.2	19
200	A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. Multiple Sclerosis and Related Disorders, 2016, 8, 99-106.	0.9	19
201	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	1.4	19
202	Emerging oral drugs for multiple sclerosis. Expert Opinion on Emerging Drugs, 2008, 13, 465-477.	1.0	17
203	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	0.9	17
204	Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Multiple Sclerosis Journal, 2001, 7, 354-358.	1.4	17
205	Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurology and Therapy, 2022, 11, 1193-1208.	1.4	17
206	The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. Neurological Sciences, 2009, 30, 163-165.	0.9	16
207	Overview of MS Spasticity. European Neurology, 2014, 71, 1-3.	0.6	16
208	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641880324.	1.5	16
209	Scoring the 10â€year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	1.7	16
210	Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis. Journal of Neurology, 2021, 268, 4834-4845.	1.8	16
211	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. Journal of the Neurological Sciences, 1999, 171, 130-134.	0.3	15
212	MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1337-1339.	1.4	15
213	Determinants of the severity of comorbid migraine in multiple sclerosis. Neurological Sciences, 2012, 33, 1345-1353.	0.9	15
214	Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod. Therapeutics and Clinical Risk Management, 2013, 9, 73.	0.9	15
215	Multiple Sclerosis Treatment and Melanoma Development. International Journal of Molecular Sciences, 2020, 21, 2950.	1.8	15
216	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. Journal of Neurology, 2021, 268, 2238-2245.	1.8	15

#	Article	IF	Citations
217	Haemodynamics and oxygen metabolism in patients after reversible ischaemic attack or minor ischaemic stroke assessed with positron emission tomography. Neuroradiology, 1987, 29, 416-421.	1.1	14
218	T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 91-96.	1.1	14
219	Clinical markers of therapeutic response to disease modifying drugs. Neurological Sciences, 2008, 29, 211-213.	0.9	14
220	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
221	Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurological Sciences, 2017, 38, 1841-1848.	0.9	14
222	Balance worsening associated with nabiximols in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 113-117.	1.4	14
223	Evidence of Impaired Brain Activity Balance after Passive Sensorimotor Stimulation in Multiple Sclerosis. PLoS ONE, 2013, 8, e65315.	1.1	14
224	HLA-DM polymorphisms do not associate with multiple sclerosis: an association study with analysis of myelin basic protein T cell specificity. Journal of Neuroimmunology, 1997, 77, 181-184.	1.1	13
225	Far transfer effect associated with video game balance training in multiple sclerosis: from balance to cognition?. Journal of Neurology, 2015, 262, 774-776.	1.8	13
226	Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis. Journal of the Neurological Sciences, 2016, 370, 211-213.	0.3	13
227	Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 153.	1.1	13
228	Efficacy of alemtuzumab over 6â€‰years in relapsingâ€“remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal, 2020, 26, 1719-1728.	1.4	13
229	Multi-scale resting state functional reorganization in response to multiple sclerosis damage. Neuroradiology, 2020, 62, 693-704.	1.1	13
230	Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 539-548.	1.4	13
231	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
232	HLA Determinants in Familial Multiple Sclerosis. Neuroepidemiology, 1992, 11, 85-89.	1.1	12
233	Down-regulation of cell-surface CD4 co-receptor expression and modulation of experimental allergic encephalomyelitis. International Immunology, 1997, 9, 541-545.	1.8	12
234	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences, 2017, 379, 236-240.	0.3	12

#	Article	IF	Citations
235	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. European Journal of Neurology, 2018, 25, 739-746.	1.7	12
236	Epidemiology and current treatment of multiple sclerosis in Europe today. Journal of Rehabilitation Research and Development, 2002, 39, 175-85.	1.6	12
237	Shift of multiple sclerosis onset towards older age. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1137-1139.	0.9	12
238	Positron Emission Tomography in Minor Ischemic Stroke Using Oxygen-15 Steady-State Technique. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 137-142.	2.4	11
239	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. Journal of the Neurological Sciences, 1998, 159, 94-101.	0.3	11
240	Cognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosis. Journal of Neuropsychology, 2020, 14, 370-383.	0.6	11
241	A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 529.	1.1	11
242	A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis. Journal of Neurology, 2021, 268, 4698-4706.	1.8	11
243	Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study. Multiple Sclerosis Journal, 2011, 17, 1177-1184.	1.4	10
244	The use of ID migraineâ„¢ questionnaire in patients with multiple sclerosis. Neurological Sciences, 2011, 32, 269-273.	0.9	10
245	Abortion induces reactivation of inflammation in relapsing-remitting multipleÂsclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1272-1278.	0.9	10
246	Long-term follow-up (up to 11Âyears) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurological Sciences, 2022, 43, 6415-6423.	0.9	10
247	Positron CT imaging of an impending stroke. Neuroradiology, 1988, 30, 276-279.	1.1	9
248	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. Journal of Neurology, 1999, 246, 97-106.	1.8	9
249	Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study. Neurological Sciences, 2003, 24, 340-345.	0.9	9
250	Interferon-beta-1a treatment has a positive effect on quality of life of relapsingâ€“remitting multiple sclerosis: Results from a longitudinal study. Journal of the Neurological Sciences, 2014, 337, 180-185.	0.3	9
251	Impaired Functional Connectivity Unmasked by Simple Repetitive Motor Task in Early Relapsing-Remitting Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 557-565.	1.4	9
252	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e591.	3.1	9

#	Article	IF	Citations
253	Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. Multiple Sclerosis and Related Disorders, 2019, 27, 239-246.	0.9	9
254	A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis. American Journal of Neuroradiology, 2021, 42, 1927-1933.	1.2	9
255	Quantitative Assessment of Cerebral Blood Flow in Partial Epilepsy Using Xe-133 Inhalation and SPECT. Clinical Nuclear Medicine, 1991, 16, 898-903.	0.7	8
256	Crossed quadrant homonymous hemianopsia in a case of multiple sclerosis. Clinical Neurology and Neurosurgery, 1995, 97, 324-327.	0.6	8
257	Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis. Multiple Sclerosis International, 2014, 2014, 1-5.	0.4	8
258	Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 236-238.	0.9	8
259	Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	8
260	Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. Neurological Sciences, 2020, 42, 2903-2910.	0.9	8
261	Facts and Trends in Cerebral Blood Flow and Metabolism: Synopsis of Brain '89. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 573-578.	2.4	7
262	Global immune disregulation in multiple sclerosis: from the adaptive response to the innate immunity. Journal of Neuroimmunology, 2000, 107, 216-219.	1.1	7
263	An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 343-347.	1.4	7
264	Extratemporal herpes encephalitis during natalizumab treatment: A case report. Multiple Sclerosis and Related Disorders, 2016, 10, 134-136.	0.9	7
265	The influence of physiotherapy intervention on patients with multiple sclerosisâ€“related spasticity treated with nabiximols (THC:CBD oromucosal spray). PLoS ONE, 2019, 14, e0219670.	1.1	7
266	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurological Sciences, 2020, 41, 2843-2851.	0.9	7
267	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis Journal, 2021, 27, 479-482.	1.4	7
268	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.5	7
269	Real time PCR for detection of Chlamydophila pneumoniae in peripheral blood mononuclear cells of patients with multiple sclerosis. Journal of Neurology, 2007, 254, 1293-1295.	1.8	6
270	Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets. Therapeutics and Clinical Risk Management, 2010, 6, 391.	0.9	6

#	Article	IF	Citations
271	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. Neuroepidemiology, 2017, 48, 171-178.	1.1	6
272	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	1.7	6
273	Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability. European Journal of Neurology, 2022, 29, 2036-2046.	1.7	6
274	Sequential Computed Tomography and ¹²³I-HIPDM Scans in Multiple Sclerosis with Large Plaque. European Neurology, 1987, 27, 88-91.	0.6	5
275	Lack of association between macrocytosis and multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1096-1096.	0.9	5
276	Pharmacological methods to overcome IFN-Î² antibody formation in the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs, 2003, 12, 1153-1163.	1.9	5
277	The MoSt Projectâ€“â€“More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. Journal of Neurology, 2014, 261, 526-532.	1.8	5
278	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Frontiers in Neurology, 2019, 10, 695.	1.1	5
279	Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. Neurotherapeutics, 2020, 17, 704-709.	2.1	5
280	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	1.1	5
281	Transcranial Doppler Ultrasonography and Single Photon Emission Tomography following Cerebral Infarction. Cerebrovascular Diseases, 1993, 3, 370-374.	0.8	4
282	Treating multiple sclerosis with fingolimod or intramuscular interferon. Expert Opinion on Pharmacotherapy, 2010, 11, 1957-1960.	0.9	4
283	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology, 2014, 71, 233-241.	0.6	4
284	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	0.9	4
285	The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis. Neuroepidemiology, 2018, 50, 105-110.	1.1	4
286	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	1.8	4
287	Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders, 2021, 49, 102717.	0.9	4
288	Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?. Biomedicines, 2022, 10, 231.	1.4	4

#	Article	IF	Citations
289	Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS). Neurological Sciences, 2022, 43, 4925-4932.	0.9	4
290	Cesarean section in women with MS: A choice or a need?. Multiple Sclerosis and Related Disorders, 2020, 38, 101867.	0.9	3
291	Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients. Frontiers in Neurology, 2021, 12, 632917.	1.1	3
292	Real world experience with Cladribine at S.Andrea Hospital of Rome. Journal of the Neurological Sciences, 2021, 429, 118113.	0.3	3
293	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	1.4	3
294	Systemic hypertension as a treatable risk factor for cerebrovascular disease. American Journal of Cardiology, 1989, 63, C19-C21.	0.7	2
295	Dynamics of the autoimmune T-cell repertoire in experimental allergic encephalomyelitis and in multiple sclerosis. Trends in Immunology, 1994, 15, 89-90.	7.5	2
296	Treatment of multiple sclerosis-related fatigue: pharmacological and non-pharmacological approaches. Neurological Sciences, 2006, 27, s297-s299.	0.9	2
297	What is Erythema Annulare Centrifugum? A Familial Case. European Journal of Inflammation, 2013, 11, 531-533.	0.2	2
298	Coping and Multiple Sclerosis. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 121-137.	0.3	2
299	Tpâ€“Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. International Journal of Cardiology, 2016, 221, 881-885.	0.8	2
300	Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 417-429.	1.4	2
301	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2021, 10, 803-818.	1.4	2
302	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 27-31.	1.4	2
303	No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis. Neurology and Therapy, 2022, 11, 471-479.	1.4	2
304	Antiphospholipid antibodies and cerebral artery dissection: Two frequent causes of brain ischemia in young adults. Italian Journal of Neurological Sciences, 1994, 15, 221-227.	0.1	1
305	Memory and executive functions in healthy subjects and patients with multiple sclerosis: the role of PET and SPECT. Italian Journal of Neurological Sciences, 1998, 19, S403-S407.	0.1	1
306	Corrigendum to â€œComputer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trialâ€•[J. Neurol. Sci. 222 (2004) 99â€“104]. Journal of the Neurological Sciences, 2004, 224, 113.	0.3	1

#	Article	IF	Citations
307	Title is missing!. Journal of the Neurological Sciences, 2005, 234, 119-120.	0.3	1
308	MRI for monitoring response to preventive treatment in multiple sclerosis. Expert Review of Neurotherapeutics, 2009, 9, 305-307.	1.4	1
309	Effects of the Bacillus Calmette-GuÃ©rin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System. , 2014, , 63-80.		1
310	Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Viral Immunology, 2017, 30, 622-626.	0.6	1
311	PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL) Tj ETQq1 1 0.784314	0.1	1
312	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	1.8	1
313	Different regimen of natalizumab treatment in multiple sclerosis patients: A real world study in Italy. Journal of the Neurological Sciences, 2019, 405, 338-339.	0.3	1
314	Long-term fingolimod treatment in two pediatric patients with multiple sclerosis. Neurological Sciences, 2021, 42, 29-36.	0.9	1
315	Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study. Multiple Sclerosis Journal, 2000, 6, 43-49.	1.4	1
316	PO152â€…Alemtuzumab efficacy in patients with relapse after course 1. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A53.1-A53.	0.9	0
317	044â€…Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A18.2-A19.	0.9	0
318	054â€…Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A22.2-A22.	0.9	0
319	Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110112.	1.5	0
320	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. Journal of the Neurological Sciences, 2021, 429, 117749.	0.3	0
321	Antinuclear antibodies and response to IFNÎ²-1a therapy in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 137-139.	1.4	0
322	[TecfideraÂ® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]. Farmeconomia E Percorsi Terapeutici, 2017, 18, .	0.2	0